415 related articles for article (PubMed ID: 18469801)
21. Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARα protein degradation.
Wang QQ; Zhou XY; Zhang YF; Bu N; Zhou J; Cao FL; Naranmandura H
Oncotarget; 2015 Sep; 6(28):25646-59. PubMed ID: 26213848
[TBL] [Abstract][Full Text] [Related]
22. Mutations affecting both the rearranged and the unrearranged PML alleles in refractory acute promyelocytic leukaemia.
Iaccarino L; Ottone T; Divona M; Cicconi L; Cairoli R; Voso MT; Lo-Coco F
Br J Haematol; 2016 Mar; 172(6):909-13. PubMed ID: 26728337
[TBL] [Abstract][Full Text] [Related]
23. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner.
Wang ZG; Rivi R; Delva L; König A; Scheinberg DA; Gambacorti-Passerini C; Gabrilove JL; Warrell RP; Pandolfi PP
Blood; 1998 Sep; 92(5):1497-504. PubMed ID: 9716575
[TBL] [Abstract][Full Text] [Related]
24. PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR.
Bernardi R; Guernah I; Jin D; Grisendi S; Alimonti A; Teruya-Feldstein J; Cordon-Cardo C; Simon MC; Rafii S; Pandolfi PP
Nature; 2006 Aug; 442(7104):779-85. PubMed ID: 16915281
[TBL] [Abstract][Full Text] [Related]
25. Stemming out of a new PML era?
Salomoni P
Cell Death Differ; 2009 Aug; 16(8):1083-92. PubMed ID: 19521423
[TBL] [Abstract][Full Text] [Related]
26. Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation.
Lallemand-Breitenbach V; Zhu J; Puvion F; Koken M; Honoré N; Doubeikovsky A; Duprez E; Pandolfi PP; Puvion E; Freemont P; de Thé H
J Exp Med; 2001 Jun; 193(12):1361-71. PubMed ID: 11413191
[TBL] [Abstract][Full Text] [Related]
27. Promyelocytic leukemia protein induces arsenic trioxide resistance through regulation of aldehyde dehydrogenase 3 family member A1 in hepatocellular carcinoma.
Zhang X; Yang XR; Sun C; Hu B; Sun YF; Huang XW; Wang Z; He YF; Zeng HY; Qiu SJ; Cao Y; Fan J; Zhou J
Cancer Lett; 2015 Sep; 366(1):112-22. PubMed ID: 26118777
[TBL] [Abstract][Full Text] [Related]
28. Selective inhibition of the NLRP3 inflammasome by targeting to promyelocytic leukemia protein in mouse and human.
Lo YH; Huang YW; Wu YH; Tsai CS; Lin YC; Mo ST; Kuo WC; Chuang YT; Jiang ST; Shih HM; Lai MZ
Blood; 2013 Apr; 121(16):3185-94. PubMed ID: 23430110
[TBL] [Abstract][Full Text] [Related]
29. How acute promyelocytic leukaemia revived arsenic.
Zhu J; Chen Z; Lallemand-Breitenbach V; de Thé H
Nat Rev Cancer; 2002 Sep; 2(9):705-13. PubMed ID: 12209159
[TBL] [Abstract][Full Text] [Related]
30. Importance of ERK activation in As2O3-induced differentiation and promyelocytic leukemia nuclear bodies formation in neuroblastoma cells.
Petit A; Delaune A; Falluel-Morel A; Goullé JP; Vannier JP; Dubus I; Vasse M
Pharmacol Res; 2013 Nov; 77():11-21. PubMed ID: 24004656
[TBL] [Abstract][Full Text] [Related]
31. CK2 and PML: regulating the regulator.
Lallemand-Breitenbach V; de Thé H
Cell; 2006 Jul; 126(2):244-5. PubMed ID: 16873055
[TBL] [Abstract][Full Text] [Related]
32. Getting to the stem of chronic myeloid leukaemia.
Savona M; Talpaz M
Nat Rev Cancer; 2008 May; 8(5):341-50. PubMed ID: 18385684
[TBL] [Abstract][Full Text] [Related]
33. Diverging fates of cells of origin in acute and chronic leukaemia.
Kovacic B; Hoelbl A; Litos G; Alacakaptan M; Schuster C; Fischhuber KM; Kerenyi MA; Stengl G; Moriggl R; Sexl V; Beug H
EMBO Mol Med; 2012 Apr; 4(4):283-97. PubMed ID: 22323443
[TBL] [Abstract][Full Text] [Related]
34. PML represses lung cancer metastasis by suppressing the nuclear EGFR-mediated transcriptional activation of MMP2.
Kuo HY; Huang YS; Tseng CH; Chen YC; Chang YW; Shih HM; Wu CW
Cell Cycle; 2014; 13(19):3132-42. PubMed ID: 25486572
[TBL] [Abstract][Full Text] [Related]
35. Interferon regulatory factor-8 is indispensable for the expression of promyelocytic leukemia and the formation of nuclear bodies in myeloid cells.
Dror N; Rave-Harel N; Burchert A; Azriel A; Tamura T; Tailor P; Neubauer A; Ozato K; Levi BZ
J Biol Chem; 2007 Feb; 282(8):5633-40. PubMed ID: 17189268
[TBL] [Abstract][Full Text] [Related]
36. Death by arsenic: implications of PML sumoylation.
Mann KK; Miller WH
Cancer Cell; 2004 Apr; 5(4):307-9. PubMed ID: 15093537
[TBL] [Abstract][Full Text] [Related]
37. Nuclear matrix associated protein PML: an arsenic trioxide apoptosis therapeutic target protein in HepG2 cells.
Yu D; Wang Z; Zhu L; Chew EC
Chin Med J (Engl); 2003 Jan; 116(1):93-8. PubMed ID: 12667397
[TBL] [Abstract][Full Text] [Related]
38. Direct transcriptional activation of promyelocytic leukemia protein by IFN regulatory factor 3 induces the p53-dependent growth inhibition of cancer cells.
Kim TK; Lee JS; Oh SY; Jin X; Choi YJ; Lee TH; Lee Eh; Choi YK; You S; Chung YG; Lee JB; DePinho RA; Chin L; Kim H
Cancer Res; 2007 Dec; 67(23):11133-40. PubMed ID: 18056437
[TBL] [Abstract][Full Text] [Related]
39. Phosphorylation of PML by mitogen-activated protein kinases plays a key role in arsenic trioxide-mediated apoptosis.
Hayakawa F; Privalsky ML
Cancer Cell; 2004 Apr; 5(4):389-401. PubMed ID: 15093545
[TBL] [Abstract][Full Text] [Related]
40. Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists.
Prost S; Relouzat F; Spentchian M; Ouzegdouh Y; Saliba J; Massonnet G; Beressi JP; Verhoeyen E; Raggueneau V; Maneglier B; Castaigne S; Chomienne C; Chrétien S; Rousselot P; Leboulch P
Nature; 2015 Sep; 525(7569):380-3. PubMed ID: 26331539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
